-
公开(公告)号：US20230400467A1
公开(公告)日：2023-12-14
申请号：US18249957
申请日：2021-10-26
申请人： COMPUGEN LTD.
发明人： Gad S. COJOCARU , Tal Fridman KFIR , Emmanuel WEYL , Amit NOVIK , Yossef KLIGER , Niv SABATH , Eran OPHIR , Zoya ALTEBER , Masha FRENKEL
IPC分类号： G01N33/574
CPC分类号： G01N33/57492 , G01N2800/52 , G01N2333/70517 , G01N2474/20
摘要： The present invention provides biomarkers for use in determining populations for treatment with anti-PVRIG antibodies and such biomarkers include, for example PVRIG and/or PVRL2 expression.
-
公开(公告)号：US11655297B2
公开(公告)日：2023-05-23
申请号：US16766224
申请日：2018-11-28
发明人： Lars Röse , Uwe Gritzan , Julia Hütter , Spencer Liang , Andrew Pow , John Hunter , Ofer Levy , Ilan Vaknin
IPC分类号： C07K16/28 , A61P35/00 , A61K31/337 , A61K31/713
CPC分类号： C07K16/2818 , A61K31/337 , A61K31/713 , A61P35/00
摘要： The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.
-
公开(公告)号：US20230070685A1
公开(公告)日：2023-03-09
申请号：US17544852
申请日：2021-12-07
申请人： Compugen Ltd.
发明人： Spencer Liang , Ling Leung , Sarah Whelan , Maya Kotturi , Eran Ophir , Arthur Machlenkin , Zoya Alteber , Meir Azulay , Sandeep Kumar , Radhika Desai , Christopher Chan , Kathryn Logronio
IPC分类号： C07K16/30 , C07K16/28 , A61K39/395 , A61P35/00
摘要： The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
-
公开(公告)号：US20230057899A1
公开(公告)日：2023-02-23
申请号：US17782635
申请日：2020-12-07
发明人： Maya Kotturi , Sarah Whelan , Paul Neeson , Jessica Li , Joseph A. Trapani , Eran Ophir , Moran Galperin
摘要： Anti-PVRIG and anti-TIGIT for use in methods of treatment based on the enhanced NK-cell using the antibodies for the treatment of cancer.
-
公开(公告)号：US20220378742A1
公开(公告)日：2022-12-01
申请号：US17773791
申请日：2020-07-28
摘要： The present invention is directed to combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.
-
公开(公告)号：US11225523B2
公开(公告)日：2022-01-18
申请号：US15996369
申请日：2018-06-01
申请人： Compugen Ltd.
发明人： Spencer Liang , Ling Leung , Sarah Whelan , Maya Kotturi , Eran Ophir , Arthur Machlenkin , Zoya Alteber , Meir Azulay , Sandeep Kumar , Radhika Desai , Christopher Chan , Kathryn Logronio
IPC分类号： C07K16/28 , A61K39/395 , C07K16/30 , A61P35/00 , A61K38/17 , C07K16/24 , C07K16/42 , G01N33/574
摘要： The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
-
公开(公告)号：US10351625B2
公开(公告)日：2019-07-16
申请号：US15896040
申请日：2018-02-13
申请人： Compugen Ltd.
发明人： Mark White , Sandeep Kumar , Christopher Chan , Spencer Liang , Lance Stapleton , Andrew W. Drake , Yosi Gozlan , Ilan Vaknin , Shirley Sameah-Greenwald , Liat Dassa , Zohar Tiran , Gad S. Cojocaru , Leonard Presta , Richard Theolis
IPC分类号： A61K39/395 , C07K16/28 , G01N33/574 , C07K7/06 , C12N15/113
摘要： The present invention is directed to anti-PVRIG antibodies and methods of using same.
-
8.发明授权Polypeptides and uses thereof for treatment of autoimmune disorders and infection 有权多肽及其用于治疗自身免疫性疾病和感染的用途公开(公告)号：US09428574B2
公开(公告)日：2016-08-30
申请号：US14129974
申请日：2012-07-01
申请人： Amir Toporik , Avi Yeshah Rosenberg , Galit Rotman , Iris Hecht , Zurit Levine
发明人： Amir Toporik , Avi Yeshah Rosenberg , Galit Rotman , Iris Hecht , Zurit Levine
IPC分类号： C07K16/18 , C07K14/705 , A61K39/395 , A61K45/06 , A61K38/00
CPC分类号： C07K14/70503 , A61K38/00 , A61K39/395 , A61K45/06 , C07K16/18 , C07K2319/30 , C07K2319/74 , C12N5/0636 , Y02A50/401
摘要： This invention relates to C1ORF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use thereof for treatment of immune related disorders and infections.
摘要翻译： 本发明涉及C1ORF32蛋白及其变体及其片段和融合蛋白，包含其的药物组合物及其用于治疗免疫相关疾病和感染的方法。
-
9.发明申请公开(公告)号：US20150299333A1
公开(公告)日：2015-10-22
申请号：US14633547
申请日：2015-02-27
申请人： Gad S. COJOCARU , Haiming CHEN , James BERENSON
发明人： Gad S. COJOCARU , Haiming CHEN , James BERENSON
IPC分类号： C07K16/30 , G01N33/574 , C12N15/113 , A61K45/06 , A61K39/395
CPC分类号： C07K16/3061 , A61K31/713 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K2317/30 , C07K2317/34 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2319/30 , C12N15/1138 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12N2320/10 , C12N2320/30 , C12Q1/6886 , G01N33/57407 , G01N33/57426 , G01N33/6893 , G01N2333/705 , A61K2300/00
摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages, wherein the cancer is relates to multiple myeloma, including multiple myeloma precursor diseases. This invention further relates to extracellular domains of TMEM154 proteins and variants, and therapeutic usages thereof.
摘要翻译： 本发明涉及用于产生免疫和非免疫的治疗剂和疾病诊断的新靶标。 更具体地，本发明提供了针对TMEM154抗原的治疗性抗体，其在癌症中差异表达，以及诊断和治疗用途，其中所述癌症涉及多发性骨髓瘤，包括多发性骨髓瘤前体疾病。 本发明进一步涉及TMEM154蛋白和变体的细胞外结构域及其治疗用途。
-
公开(公告)号：US20140294765A1
公开(公告)日：2014-10-02
申请号：US14361571
申请日：2013-06-19
申请人： Compugen Ltd.
发明人： Gad S. Cojocaru , Liat Dassa , Galit Rotman , Ofer Levi , Andrew Pow , Shirley Sameach-Greenwald , Zurit Levine
IPC分类号： C07K16/28 , G01N33/574 , A61K31/675 , A61K45/06 , A61K39/395
CPC分类号： A61K31/675 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/507 , C07K14/70503 , C07K16/28 , C07K16/2818 , C07K16/2878 , C07K16/30 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/734 , C07K2319/30 , C12N15/1138 , C12N2310/14 , G01N33/57492 , G01N2800/24 , G01N2800/26 , Y02A50/412 , Y02A50/423 , A61K2300/00
摘要： This invention relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for LSR molecules, which are suitable drugs for immunotherapy and treatment of specific cancer.
摘要翻译： 本发明涉及对于LSR分子特异性的抗体和抗原结合片段和含有其的缀合物和/或替代性支架，其是用于免疫治疗和治疗特定癌症的合适药物。
-
-
-
-
-
-
-
-
-
搜索结果
127 条记录 (耗时 0.053 秒)
